Original news and analysis on international IP policy
Médecins Sans Frontières (MSF, Doctor Without Borders) today announced a report detailing what it calls failings in the current system for developing new drugs in ways that all patients can afford and access, and providing proposed policy options for addressing the problems.
The World Health Organization interacts with a large number of actors aside from governments, such as industry, philanthropic organisations, academia, and civil society. With an eye to preventing undue influence on the work of the organisation, member states have been trying to finalise a draft framework on WHO interaction with those actors. This week, what was seen as a last effort at reaching a consensual text did not quite meet the goal and some additional informal discussions are expected to take place before the annual World Health Assembly in late May.
James Love writes: In a recent paper by Reed F. Beall and Amir Attaran [KEI's April 12, 2016 comment here: http://www.keionline.org/node/2467], and in the WIPO seminar discussions about the paper, the authors have held themselves out as more or less lonely voices calling for transparency of patent landscapes on essential medicines. This surprised and offended the many people who have not only been concerned about the lack of transparency on patent landscapes, but have been doing most of the work in digging out the facts, and/or proposing remedies.
The recent Geneva Health Forum captured the fevered pitch in the larger ongoing conversation around innovative financing for research and development for public health. A new report on a voluntary pooled fund for neglected diseases was discussed at the forum.
This week a group of delegates at the UN World Health Organization is seeking to finalise agreement on a draft framework defining the organisation’s relationships with external actors, such as philanthropy, the private sector, academia, and civil society. Today, Norway put forward a potential compromise. Meanwhile, dozens of civil society organisations called on member states to stand up to pressure to compromise the intergovernmental body’s independence from private sector influence.
The Medicines Patent Pool announced today that its current licensing agreement with ViiV Healthcare for a new antiretroviral drug will be extended to all lower middle-income countries.
Members of a team reviewing at the World Health Organization framework for ensuring global pandemic influenza preparedness moved ahead with their proceedings last week. They found both support for the framework, and also concerns.
Five years after its adoption, a World Health Organization mechanism to help the world be ready for future influenza pandemics is being reviewed. According to several stakeholders invited to share their views, a major challenge is genetic sequence data, which allows digital reproduction of material. Other issues include the relationship of the mechanism to an international convention on access to genetic resources, and the contribution of industry.
In light of the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
The World Health Organization has released a report on the role of intellectual property in local production of medicines in developing countries. According to the report, the way countries design their intellectual property system is key in the development of local innovation and production. However, health outcomes will depend on the accessibility and affordability of good-quality essential medicines.